ZA932731B - Method of treating gar-transformylase-dependent tumors - Google Patents
Method of treating gar-transformylase-dependent tumorsInfo
- Publication number
- ZA932731B ZA932731B ZA932731A ZA932731A ZA932731B ZA 932731 B ZA932731 B ZA 932731B ZA 932731 A ZA932731 A ZA 932731A ZA 932731 A ZA932731 A ZA 932731A ZA 932731 B ZA932731 B ZA 932731B
- Authority
- ZA
- South Africa
- Prior art keywords
- transformylase
- gar
- treating
- dependent tumors
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87246992A | 1992-04-23 | 1992-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA932731B true ZA932731B (en) | 1994-10-19 |
Family
ID=25359620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA932731A ZA932731B (en) | 1992-04-23 | 1993-04-19 | Method of treating gar-transformylase-dependent tumors |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0567324A1 (xx) |
JP (1) | JPH07258088A (xx) |
KR (1) | KR930021204A (xx) |
AU (1) | AU663369B2 (xx) |
CA (1) | CA2094687A1 (xx) |
CZ (1) | CZ66893A3 (xx) |
HU (1) | HUT64226A (xx) |
ZA (1) | ZA932731B (xx) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT405924B (de) | 1998-01-16 | 1999-12-27 | Oskar Wachauer | Antrieb für ein fahrzeug, insbesondere für ein mehrspuriges elektromobil |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA861235B (en) * | 1985-03-08 | 1986-10-29 | Univ Princeton | Pyrido(2,3-d)pyrimidine derivatives |
JP2830008B2 (ja) * | 1988-04-01 | 1998-12-02 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体 |
DK172753B1 (da) * | 1988-05-25 | 1999-06-28 | Lilly Co Eli | N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat |
-
1993
- 1993-04-19 ZA ZA932731A patent/ZA932731B/xx unknown
- 1993-04-19 CZ CZ93668A patent/CZ66893A3/cs unknown
- 1993-04-21 KR KR1019930006748A patent/KR930021204A/ko not_active Application Discontinuation
- 1993-04-21 EP EP93303117A patent/EP0567324A1/en not_active Withdrawn
- 1993-04-21 AU AU37053/93A patent/AU663369B2/en not_active Ceased
- 1993-04-22 CA CA002094687A patent/CA2094687A1/en not_active Abandoned
- 1993-04-22 HU HU9301187A patent/HUT64226A/hu unknown
- 1993-04-22 JP JP5095784A patent/JPH07258088A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
HU9301187D0 (en) | 1993-07-28 |
EP0567324A1 (en) | 1993-10-27 |
CA2094687A1 (en) | 1993-10-24 |
AU663369B2 (en) | 1995-10-05 |
AU3705393A (en) | 1993-10-28 |
JPH07258088A (ja) | 1995-10-09 |
KR930021204A (ko) | 1993-11-22 |
HUT64226A (en) | 1993-12-28 |
CZ66893A3 (en) | 1993-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9119557D0 (en) | Method of treating hair | |
GB9027968D0 (en) | Method of treatment | |
GB2269393B (en) | Method of treating MCrAlZ layers | |
AU3973793A (en) | Method of treating cancer | |
GB9218027D0 (en) | Novel method of treatment | |
EP0562848A3 (en) | Surface treating method | |
GB9217998D0 (en) | Methods of treating cancer | |
GB9202196D0 (en) | Method of treatment | |
ZA932731B (en) | Method of treating gar-transformylase-dependent tumors | |
PH30221A (en) | Method of treating ketosis | |
ZA935831B (en) | Methods of treating psoriasis employing substituted azaspiranes | |
GB9201391D0 (en) | Method of treatment | |
GB9218597D0 (en) | Novel method of treatment | |
EP0705104A4 (en) | ANTI-CANCER THERAPY | |
GB9218188D0 (en) | Method of treatment | |
GB9202020D0 (en) | Method of treatment | |
GB9223252D0 (en) | Method of treatment | |
GB9207275D0 (en) | Method of treatment | |
GB9202698D0 (en) | Method of treatment | |
GB9226252D0 (en) | Method of treatment | |
GB9226371D0 (en) | Novel method of treatment | |
ZA922012B (en) | New method of treatment for prostatic cancer | |
GB9101175D0 (en) | Method of treatment | |
GB9105617D0 (en) | Method of treatment | |
GB9101176D0 (en) | Method of treatment |